Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015370 | 0.90 | KDM4E (0.60) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL1800974 | 0.84 | ALDH1A1 (0.57) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| SCHEMBL7467356 | 0.82 | KMT2A (0.56) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL7935548 | 0.81 | KMT2A (0.55) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL4733777 | 0.81 | KMT2A (0.55) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL6510276 | 0.81 | KMT2A (0.68) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL25658467 | 0.79 | NPC1 (0.66) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31058534 | 0.78 | ALDH1A1 (0.58) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL11775995 | 0.78 | ALDH1A1 (0.58) | KDM4EALDH1A1HSD17B10MAPTMEN1 | |
| SCHEMBL4784357 | 0.78 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | KDM4E 4309/4885ALDH1A1 800/4885HSD17B10 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.